Oncolytic virotherapy, Nat Biotechnol, vol.30, pp.658-670, 2012. ,
Going viral with cancer immunotherapy, Nat Rev Cancer, vol.14, pp.559-567, 2014. ,
Consensus guidelines for the detection of immunogenic cell death, Oncoimmunology, vol.3, p.955691, 2014. ,
Innate immune pattern recognition: a cell biological perspective, Annu Rev Immunol, vol.33, pp.257-290, 2015. ,
Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells, Oncoimmunology, vol.2, p.24212, 2013. ,
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response, Cancer Res, vol.68, pp.4882-4892, 2008. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00330770
Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells, Clin Cancer Res, vol.19, pp.1147-1158, 2013. ,
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, vol.33, pp.2780-2788, 2015. ,
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer, J Urol, vol.188, pp.2391-2397, 2012. ,
Reovirus therapy of tumors with activated Ras pathway, Science, vol.282, pp.1332-1334, 1998. ,
The oncolytic virus, pelareorep, as a novel anticancer agent: a review, Invest New Drugs, vol.33, pp.761-774, 2015. ,
Randomized dosefinding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat Med, vol.19, pp.329-336, 2013. ,
, Global Partners SillaJen, Transgene and Lee's Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec, Transgene, 2014.
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer, Cancer Res, vol.75, pp.22-30, 2015. ,
Antitumor Virotherapy by Attenuated Measles Virus (MV), Biology (Basel), vol.2, pp.587-602, 2013. ,
Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis, J Virol, vol.87, pp.3484-3501, 2013. ,
Orchestrating immune check-point blockade for cancer immunotherapy in combinations, Curr Opin Immunol, vol.27, pp.89-97, 2014. ,
, Recent Progresses of Oncolytic Immunotherapy, Citation: Fonteneau JF, vol.1, p.101, 2015.